

SPARC/Sec/SE/2022-23/113

February 24, 2023

To,

National Stock Exchange of India Ltd., Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051. BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Ref: Scrip Code: NSE: SPARC; BSE: 532872

Dear Sir/Madam,

Sub: Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby furnish the details of request for issue of duplicate share certificate reported by shareholder of the Company, received from our Registrar and Transfer Agent, Link Intime India Private Limited on February 24, 2023

Accordingly, in compliance with the SEBI Circular No. SEBI/HO/MIRSD /MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022, a Letter of Confirmation in lieu of the original share certificate will be issued to the respective shareholders of the Company, as provided below:

Name of the Shareholder(s)	Folio No.	Dist. Nos From - To (Both Inclusive)	New Certificate No.	No. of Shares
Johnfrancis Mathew Menezes	011661	207126282 -207126283	8387	2

We request you to kindly take the same on record.

Yours faithfully,

For Sun Pharma Advanced Research Company Limited

Dinesh Lahoti Company Secretary and Compliance Officer ICSI Membership No. A22471